JBC Origene Your Gene Company

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M309022200 on March 26, 2004

J. Biol. Chem., Vol. 279, Issue 25, 26019-26027, June 18, 2004
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/25/26019    most recent
M309022200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nho, C. W.
Right arrow Articles by O'Dwyer, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nho, C. W.
Right arrow Articles by O'Dwyer, P. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

NF-{kappa}B Activation by the Chemopreventive Dithiolethione Oltipraz Is Exerted through Stimulation of MEKK3 Signaling*

Chu Won Nho and Peter J. O'Dwyer{ddagger}

From the Division of Hematology-Oncology, School of Medicine and Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104

Received for publication, August 14, 2003 , and in revised form, March 24, 2004.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Chemoprevention by the dithiolethione analogue oltipraz (4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione) may occur through several mechanisms, among them stimulation of detoxication activity. The phase II detoxication enzyme, NAD(P)H:quinone oxidoreductase 1 (NQO1; EC 1.6.99.2 [EC] ) also known as quinone reductase (QR) is well established to undergo transcriptional activation following oltipraz treatment of colon cancer cells in culture. Promoter analysis of the QR gene in oltipraztreated cells reveals the involvement of both the AP-1 and NF-{kappa}B elements in the response. The emerging role of NF-{kappa}B in cell survival prompted a fuller analysis of effects of oltipraz on this pathway. Oltipraz treatment of both HCT116 and HT29 cells results in the induction of proteins involved in both pathways of NF-{kappa}B activation, including p65, I{kappa}B kinase {alpha} (IKK{alpha}), I{kappa}B kinase {beta} (IKK{beta}), and NF-{kappa}B-inducing kinase (NIK). I{kappa}B{alpha} total protein levels were unchanged, but phosphorylation of the inhibitor was also induced in both lines. Electrophoretic mobility shift assay (EMSA) analysis confirmed induction of protein binding to a consensus NF-{kappa}B element, and transcriptional activation was further confirmed using a reporter construct. Transcriptional activation of QR was decreased in a dose-dependent manner by dominant-negative NF-{kappa}B in both cell lines. The molecular mechanism that triggers IKK activation in response to oltipraz was also examined using inhibitory constructs of NIK and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 3 (MEKK3). We found that both MEKK3 and NIK exert effects on IKK{alpha}/{beta} activation, but through different pathways. Furthermore, the receptor-interacting protein (RIP) was found to interact strongly with MEKK3 during oltipraz-induced NF-{kappa}B signaling, implying a role for tumor necrosis factor receptor signaling in the action of oltipraz. These results implicate a novel signaling pathway for the action of oltipraz in QR gene regulation.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Prevention of cancer through the administration of inexpensive non-toxic molecules has the potential to decrease the incidence of this important disease (1). Compounds with established success include anti-estrogens for breast cancer prevention (2, 3), aspirin for colon cancer prevention (4), and retinoids to prevent second primaries on patients with head and neck cancer (2). Micronutrients and other natural products are being explored in other cancers. Novel candidate molecules with defined chemopreventive mechanisms are needed.

Oltipraz is a synthetic dithiolethione with experimental support for its role as a chemoprevention agent. Dithiolethiones are constituents of the Brassica family of green leafy vegetables, high consumption of which has been shown to lower cancer risk (5, 6). Cruciferous vegetables of the Brassica family, such as broccoli and Brussels sprouts, appear to be most effective in this regard (7, 8). Oltipraz has several proposed mechanisms of action, including induction of detoxication pathways (9), DNA repair stimulation (10), and alteration of the expression of additional genes that may relate to carcinogenesis (11).1 Studies in various models of carcinogenesis have shown protection by oltipraz from the induction of cancers in skin, breast bladder, lung, colon, pancreas, stomach, and liver (11). Clinical trials have established that induction of detoxication pathways can be achieved at tolerable doses of oltipraz (12), though a large scale study in China produced mixed results (13). Furthermore, doses that produce pharmacological activity are also associated with some skin and neurological toxicity that limit the therapeutic potential of the agent (14). It is critical therefore to understand the mechanism of chemoprevention by oltipraz so that targets for this activity can be identified, and candidate molecules with an improved toxicity profile tested against them.

We have previously examined the effects of oltipraz on regulation of detoxication enzymes, including glutathione transferases and quinone reductase (15). We also have reported that transcriptional regulation of the QR2 gene involves the stimulation by oltipraz of a number of transcription factors, including activating protein-1 (AP-1), and nuclear factor kappa-B (NF-{kappa}B) (16, 17). Although NF-{kappa}B alone seems to account for only 20–30% of QR promoter activity revealed by mutational analysis, NF-{kappa}B is responsible for a proportion of the immediate response on the QR gene promoter, and it is of interest based on the pleiotropic range of cells and promoters in which it is active. In addition, the anti-apoptotic role of NF-{kappa}B in many transformed cells may have implications for its potential role in chemoprevention.

The NF-{kappa}B family of transcription factors were identified as regulators of genes involved in coordinating immune responses, and subsequently found to be active in other cell types. NF-{kappa}B is composed of homo-and heterodimers of five members of the Rel family including RelA (p65), RelB, c-Rel, NF-{kappa}B1 (p50), and NF-{kappa}B2 (p52). Two mechanisms for their activation have been described. In one, NF-{kappa}B proteins are present in the cytoplasm in an inactive form, bound by inhibitor molecules that include I{kappa}B{alpha}, I{kappa}B{beta}, and I{kappa}B{epsilon}. In the second, the inactive precursor forms of p50 and p52, p105 and p100 respectively are present unassociated with the inhibitors (18). Activation of NF-{kappa}B may be triggered by a signaling cascade that results in phosphorylation of I{kappa}B by an I{kappa}B kinase (IKK) complex composed of IKK{alpha}, IKK{beta}, and IKK{gamma}, the activity of which results in the release and subsequent proteasomal degradation of I{kappa}B (19). In the alternative pathway, partial degradation of the p100 precursor by proteolysis releases active p52, which permits translocation to the nucleus of preformed p52-RelB complexes (20, 21). The enzyme responsible for the activation of p100 proteolysis is NIK (22), which activates IKK{alpha}, which in turn acts on p100 to direct it toward proteasomal processing and release of p52 (23, 24). This alternative pathway has shown to be involved in signaling cascades that act in the development, organization, and function of lymphoid tissue.

The molecular mechanism(s) by which the IKK complex is activated is an active area of current investigation. There are several potential upstream IKK kinases, including MEKK1 (25), MEKK2 (26), MEKK3 (26), NIK (27), TNF receptor-associated factor (TRAF) binding kinase 1 (TBK1, also known as TRAF2-associated kinase; T2K, or NF-{kappa}B-activating kinase, NAK) (28) and transforming growth factor-{beta}-activating kinase (TAK1) (29), all of which have been shown to phosphorylate and activate IKK directly in vitro. A recent study confirmed that MEKK3 is essential for TNF-induced NF-{kappa}B activation (30). The authors found that MEKK3 acted downstream of TRAF2 and receptor-interacting protein (RIP). In addition, MEKK3 was found to interact with RIP physically (37).

To pursue further the role of NF-{kappa}B in QR gene regulation and more broadly in chemoprevention, we investigated the effects of oltipraz treatment on the upstream events that signal NF-{kappa}B transactivation. We report here that NF-{kappa}B activation by oltipraz in colon cancer cells occurs primarily by activation of MEKK3 followed by IKK{alpha} and IKK{beta} activation. Evidence of activation of NIK was also demonstrated, but signaling through p100 did not appear to be important. A possible role for TNF-{alpha} receptor signaling in mediating the pharmacological effect is suggested by the involvement of the RIP-MEKK3 complex in the response.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Reagents and Constructs—Oltipraz was purchased from LKT Labs (>99% purity, St. Paul, MN) and dissolved in Me2SO (stock solution is 50 mM). TNF-{alpha} was purchased from BD Biosciences (San Diego, CA) and dissolved in Me2SO (stock solution is 100 µg/ml). The NF-{kappa}B reporter plasmid containing four copies of an NF-{kappa}B binding site (pNF-{kappa}B-Luc) and its control vector (pTAL-Luc) were purchased from Clontech (Palo Alto, CA). The structure of the human pDTD890-CAT construct has been described previously (31). pCAT-Basic vector, pCMV-{beta}-gal vector, and pRL-CMV were purchased from Promega (Madison, WI). Mammalian expression vectors for HA-tagged RIP-(1–300) and RIP-(569–671) were provided from Dr. Toshiyuki Miyashita (National Research Institute, Tokyo, Japan). Dominant-negative mutants of NF-{kappa}B signaling, I{kappa}BSR, and dnNIK (NIKKK429-AA430) were provided by Dr. Karen Vousden (NCI, National Institutes of Health, Bethesda, MD).

Cell Lines and Cell Treatments—HT29 and HCT116 colon adenocarcinoma cells were grown in Dulbecco's modified Eagle's medium with 10% fetal bovine serum at 37 °C in a humidified atmosphere of 95% air/5% CO2. Cells were plated at a density of 5 x 105 cells per 100-mm dish 24 h prior to 100 µM oltipraz and 0.02% Me2SO treatment (solvent control). The cells were exposed to oltipraz for 24 h, after which oltipraz was removed, and fresh medium added for further incubation. Total RNA or protein extracts were isolated from the cells at various times (0, 6, 24, 30, and 48 h).

Cytosolic and Nuclear Extract Preparation—Nuclear and cytosolic proteins were prepared using CelLyticTM NuCLEARTM Extraction Kit (Sigma) according to the manufacturer's manual. Briefly, the cells were washed with cold phosphate-buffered saline and collected in conical centrifuge tubes. After a 5-min centrifugation, the pellet was resuspended in a 1x hypotonic lysis buffer containing the protein inhibitors; aprotinin (2 µg/ml), leupeptin (2 µg/ml), pepstatin (5 µg/ml), 1 mM phenylmethylsulfonyl fluoride, and 1 mM dithiothreitol. The resuspended cells were centrifuged at 420 x g for 5 min 4 °C. The pellet was again resuspended with the lysis buffer and disrupted using a glass tissue homogenizer. The disrupted cells were centrifuged for 30 min at 20,000 x g at 4 °C, and the supernatant saved as a cytosolic extract. The pellet was resuspended in extraction buffer (20 mM Hepes, pH 7.9, 1.5 mM MgCl2, 0.42 M NaCl2, 0.2 mM EDTA, 25% (v/v) glycerol) containing the protein inhibitors: aprotinin (2 µg/ml), leupeptin (2 µg/ml), pepstatin (5 µg/ml), 1 mM phenylmethylsulfonyl fluoride, and 1 mM dithiothreitol. The resuspension was incubated on ice for 30 min with gentle shaking and centrifuged at 20,000 x g for 5 min. The supernatant was stored as a nuclear extract at –80 °C.

Western Blotting—Cytosolic or nuclear protein (10–15 µg per well) was separated on 10% SDS-polyacrylamide gels and transferred onto nitrocellulose membranes for Western blot analysis. Antibodies against p65 (RelA), p50, I{kappa}B{alpha}, NIK, and NQO1 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA); IKK{alpha}, IKK{beta}, and p-I{kappa}B{alpha} antibody was purchased from Cell Signaling Technology (Beverly, MA); and anti-MEKK3 antibody was purchased from BD Transduction Laboratories (San Diego, CA). A blocking monoclonal antibody against TNF-R1 (clone 55R-170) was purchased fromR&D Systems (Minneapolis, MN). HCT116 cells were incubated with TNF-R1 blocking antibody (25 µg/ml) for 1 h prior to TNF-{alpha} (100 ng/ml) or oltipraz (100 µM) treatment for 1 or 24 h, respectively. Following treatments, the cells were harvested and subjected to Western blotting with specific antibodies against TRADD, RIP, TRAF2, and IKK{beta}. TRADD and TRAF2 antibodies were purchased from BD Transduction Laboratories.

Northern Blotting—Total RNA was isolated using TRIzol reagent (Invitrogen) following the manufacturer's instructions. Total RNA (15 µg) was electrophoresed, transferred onto nitrocellulose membranes, and hybridized to a 1.2-kb human quinone reductase probe (32) at 65 °C. Membranes were washed for 1 h in 2x SSC (1x SSC: 0.3 M NaCl, 0.03 M sodium citrate, pH 7.0) containing 0.5% SDS and exposed to autoradiography.

Electrophoretic Mobility Shift Assay (EMSA)—The NF-{kappa}B site in the human quinone reductase promoter region, 5'-TCAGTACAGACGGGGCTTCACCAGGTTGGCCAG-3' was first labeled with [{gamma}-32P]ATP using polynucleotide kinase (Promega). 10 µg of nuclear extracts were incubated with gel shift binding buffer (50 mM Tris-HCl, pH 7.5, 5 mM MgCl2, 2.5 mM EDTA, 2.5 mM dithiothreitol, 250 mM NaCl, 0.25 µg/µl poly(dI:dC), 20% glycerol) for 10 min. The NF-{kappa}B or control Oct-1 probe was labeled with [{gamma}-32P]ATP (greater than 50,000 cpm/ml), and samples were incubated for a further 20 min at room temperature. The samples were separated on a 6% polyacrylamide gel in 0.5x Tris borate/EDTA buffer at 200 V. The gels were dried and developed by autoradiography.

Transfection and Reporter Gene Analysis—HT29 and HCT116 cells were plated at 5 x 104 cells per well in 6-well plates 24 h prior to transfection. The cells were transfected using the FuGENE transfection reagent (Invitrogen) with 1 µg of pNF-{kappa}B-Luc or 1 µg of pTAL-Luc, in combination with 0.1 µg of pRL-CMV vector (Promega). pRL-CMV directs expression of Renilla luciferase under a constitutive promoter and was used as an internal control to normalize the obtained NF-{kappa}B values. After 24 h of transfection, cells were treated with 100 µM oltipraz as above, lysed, and subjected to the luciferase assay using the Dual-Luciferase Reporter System (Promega) on the TD20/20 Luminometer (Turner Design, Sunnyvale, CA). The relative light units (RLUs) were calculated as the ratio of firefly luciferase to Renilla luciferase luminescence. Nonspecific luciferase activation was determined in parallel experiments with pTAL-Luc (control vector) and deducted. Normalized luciferase activities are presented as fold induction relative to the activity obtained from the Me2SO control group. The cells were transfected as above with 1 µg of pDTD890-CAT or 1 µg of its control vector (pCAT-Basic vector) in a combination with 0.5 µg of pCMV-{beta}-gal. CAT protein produced was determined using the CAT-ELISA kit (Roche Applied Science) according to the manufacturer's instructions on an ELx 800 Universal Microplate Reader (BIO-TEK, INC). Nonspecific CAT activation was determined in parallel experiments with pCAT-Basic (control vector) and was deducted. The transfection efficiency between samples was corrected with values of {beta}-galactosidase expression measured by the {beta}-gal-ELISA kit (Roche Applied Science). Normalized CAT activities were presented as fold induction relative to the activity obtained from the Me2SO control group. All reporter gene experiments were performed three times in triplicate.

Construction of siRNA-MEKK3 and Transfection—Two DNA oligonucleotides (53–61 nt in size) were designed to produce 19-nt siRNAs. In the forward oligonucleotide, the 19-nt sense siRNA sequence is linked to the reverse complementary antisense siRNA sequence by a short spacer. In the reverse oligonucleotide, 4-nt overhangs to the EcoRI and ApaI restriction sites were added to the 5'- and 3'-end of the 54-nt sequence complementary to the forward oligonucleotide, respectively. The sequences for the bodies of siRNAs for MEKK3 were taken from GenBankTM accession number U78876 [GenBank] (nucleotides 416–434). Two oligonucleotides were mixed in equimolar amounts, heated for 5 min at 95 °C, then gradually cooled to room temperature in annealing buffer (10 mM Tris-HCl, 100 mM NaCl, pH 7.4). The annealed siRNA insert was subcloned into the EcoRI and ApaI restriction sites of pSilencer 1.0-U6 vector (Ambion, Austin, TX). 5 µg of siRNA-MEKK3 plasmid and its control plasmid (pSilencer 1.0-U6) were transfected into HCT116 cells in 100-mm dishes (5 x 105) for protein extraction. For luciferase activity, the cells (5 x 104) were co-transfected with 1 µg of siRNA-MEKK3 plasmid or pNF-{kappa}B-Luc or the respective empty expression vectors (pSilencer 1.0-U6 or pTAL-Luc), in combination with 0.1 µg of pRL-CMV vector (Promega). The luciferase activity was analyzed as described above and all transfection experiments were performed three times in triplicate.

Immunoprecipitation and Kinase Assay—For immunoprecipitation assays, HCT116 cells (5 x 105) were treated with 100 µM oltipraz for 24-48 h and lysed in 1 ml of lysis buffer (50 mM HEPES, pH 7.6, 250 mM NaCl, 0.1% Nonidet P-40, 5 mM EDTA, 1 µg/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride). 500 µg of protein extracts in each sample were precipitated with 2 µg of anti-RIP antibody (obtained from BD Transduction Laboratories) and further incubated with protein A-agarose beads overnight at 4 °C. The beads were washed four times with lysis buffer, and bound proteins were resolved in 10% SDS-polyacrylamide gels and detected by Western blotting. Endogenous IKK was immunoprecipitated with 1 µg of anti-IKK{alpha} and anti-IKK{beta} antibody and an in vitro kinase assay performed by incubating them at 30 °C for 30 min in a reaction buffer containing 1 µg of GST-I{kappa}B{alpha}-(1–317) as substrate (obtained from Santa Cruz Biotechnology), [{gamma}-32P]ATP and 100 µM cold ATP in the kinase buffer (25 mM Tris-HCl, pH 7.5, 5 mM {gamma}-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4, 10 mM MgCl2). After the kinase reaction was stopped by adding 2x SDS sample buffer, phosphorylation of I{kappa}B{alpha} was analyzed by 10% SDS-PAGE followed by autoradiography. To monitor IKK{alpha}/{beta} protein content in each kinase reaction, Western blotting was done on the same membrane using anti-IKK{alpha}/{beta} antibodies.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Oltipraz Induces NF-{kappa}B Signaling Pathways—Although most of the individual regulatory elements (including AP-1 and NF-{kappa}B binding sites) have been identified in the QR promoter region (31, 33), the particular signaling cascades involved in its regulation have yet to be described. A few reports have defined the upstream signals for detoxication enzyme activation upon treatment with dietary components such as isothiocyanates (34, 35). In our previous work we found that NF-{kappa}B is one of the key transcription factors involved in quinone reductase gene regulation by oltipraz (16, 31), though the upstream signaling events leading to NF-{kappa}B activation have not been described. To analyze the basis for NF-{kappa}B activation, we investigated the expression of key proteins involved in its activation pathway. Increases in the cellular content of p65, p50, IKK{alpha}, and IKK{beta} occurred in a time-dependent manner following exposure to 100 µM oltipraz in both HT29 and HCT116 cells (Fig. 1). I{kappa}B{alpha} degradation was not observed, but phosphorylation of I{kappa}B{alpha} was markedly increased in a time-dependent manner. This finding is consistent with previous reports suggesting that incomplete degradation of I{kappa}B{alpha} is sufficient for NF-{kappa}B activation in certain types of colon epithelial cells including HT29 cells (36, 37). To analyze the functional status of NF-{kappa}B protein complexes induced by oltipraz, we performed EMSA assays. The binding activity on the NF-{kappa}B binding site in the regulatory region of QR was increased by oltipraz in both cell lines (Fig. 2, top panel). The binding activities gradually increased from 6 to 48 h post-treatment. No effect of oltipraz was observed on binding to the Oct-1 element (Fig. 2, lower panel). To confirm transcriptional activation of the NF-{kappa}B element in QR by oltipraz, we conducted a transfection experiment using a reporter construct containing the NF-{kappa}B element found in the regulatory region of the human QR gene (Fig. 3A). NF-{kappa}B activation was significantly induced in both HT29 and HCT116 cells, with minor differences between them in the degree of the response. To provide further functional evidence for NF-{kappa}B involvement in oltipraz-induced signaling, we used a dominant-negative mutant of NF-{kappa}B(I{kappa}BSR, I{kappa}B superrepressor) and a dominant-negative mutant of the upstream kinase, dnNIK (dominant-negative NIK). I{kappa}BSR cannot be phosphorylated and therefore precludes degradation of I{kappa}B. dnNIK, is a kinase-inactive mutant of NIK that lacks the two lysine residues in its catalytic domain (NIKKK429–430AA), and so behaves as a dominant-negative inhibitor to suppress NF-{kappa}B activity. HCT116 cells were co-transfected with the pNF-{kappa}B-Luc vector together with various concentrations of I{kappa}BSR or dnNIK or its empty expression vector, pcDNA3.1. After 24 h of transfection, the cells were treated with 100 µM oltipraz for an additional 24 h and analyzed for luciferase activity. Oltipraz-induced NF-{kappa}B transcriptional activity was decreased by I{kappa}BSR and dnNIK in a dose-dependent manner, and 1 µg of I{kappa}BSR or dnNIK completely abrogated the effect of oltipraz on NF-{kappa}B activation in HCT116 cells (Fig. 3B). Taken together, these results confirm that oltipraz clearly induces NF-{kappa}B signaling in colon cancer cells, and together with our previous data (16, 31), show that the pathway is an important component in induction of QR detoxication activity in these cells.



View larger version (39K):
[in this window]
[in a new window]
  		FIG. 1.
Oltipraz activates NF-{kappa}B signaling. Effects of oltipraz on protein expression involved in NF-{kappa}B signaling including p65, p50, I{kappa}B{alpha}, phosphorylated-I{kappa}B{alpha} (p-I{kappa}B{alpha}), IKK{alpha}, and IKK{beta} in HT29 and HCT116 cells. The cells (5 x 105) were treated with Me2SO (0 h control) or 100 µM oltipraz for the time periods indicated and were analyzed by Western blotting with various antibodies. An anti-actin antibody was used to show equal loading of protein. Quantitation of the Western blots was performed by densitometric scanning of the film using an image analysis system, ImageQuant 5.0 software. Densitometry readings of the bands were normalized to actin levels and expressed as fold induction relative to control (0 h). The numbers below each band represent the mean fold induction of protein levels based on densitometric analysis from three independent experiments. *, values differing statistically from control (p < 0.05; Student's t test).

 



View larger version (50K):
[in this window]
[in a new window]
  		FIG. 2.
Oltipraz increases NF-{kappa}B binding activities. Nuclear protein was extracted from the cells (5 x 105) treated with Me2SO (0 control) or 100 h µM oltipraz for 6, 24, 48 h in HT29 and HCT116 cells. 10 µg of nuclear extract from each sample was used for EMSA using either NF-{kappa}B (top panel) or Oct-1 (lower panel) oligonucleotide as probes. Specific anti-p65 antibody was added to the reaction mixtures of 24 h-treated cells prior to incubation with the labeled probe (lanes 6 and 12). A competition experiment was also performed with a 100-molar excess of unlabeled NF-{kappa}B oligonucleotide (lanes 5 and 11). Results from one of five independent experiments are shown.

 



View larger version (40K):
[in this window]
[in a new window]
  		FIG. 3.
Oltipraz increases the transcriptional activation of NF-{kappa}B. A, effect of oltipraz on NF-{kappa}B transcriptional activation in HT29 and HCT116 cells. The cells (5 x 104) were co-transfected with 1 µg of pNF-{kappa}B-Luc or 1 µg of pTAL-Luc vector, in a combination with 0.1 µg of pRL-CMV vector for 24 h and then treated with Me2SO 100 (control) or µM oltipraz for an additional 24 h. After the treatment, cells were lysed and analyzed using a Dual-Luciferase Reporter System as described under "Experimental Procedures." Normalized luciferase activities were presented as fold induction relative to the activity obtained from the control group. The data shown are means ± S.D. of three independent experiments done in triplicate. The statistical significance of the difference between control and oltipraz-treated group was assessed by the two-sample Student's t test between two paired samples. One asterisk denotes the statistically significant difference with p values less than 0.05. B, effect of the dominant negatives I{kappa}BSR and dnNIK on NF-{kappa}B transcriptional activation in oltipraz-treated HCT116 cells. The cells (5 x 104) were co-transfected with 0.1 µg of pRL-CMV vector and 1 µg of pNF-{kappa}B-Luc or pTAL-Luc vector together with the indicated amount (µg) of the I{kappa}BSR or dnNIK, or the empty expression vector, pcDNA3.1. After 24 h of transfection, the cells were treated with Me2SO (control) or 100 µM oltipraz for an additional 24 h. Normalized luciferase activities are presented as fold induction relative to the activity obtained from the control group. The data shown are means ± S.D. of three independent experiments done in triplicate.

 
Human QR Gene Expression Is Decreased by Dominant-negative Mutants of NF-{kappa}B Signaling—We have previously shown that NF-{kappa}B is involved in the control of QR gene expression using mutational analysis of the QR promoter region (31). To demonstrate further the functional consequences of NF-{kappa}B activation by oltipraz for QR gene expression, we co-transfected HCT116 cells with I{kappa}BSR or dnNIK together with pDTD890-CAT, a construct that contains the regulatory region (from –1 to –890) of the human QR gene. After 24 h of transfection, cells were exposed to oltipraz for 24 h, and CAT activity was measured. As shown in Fig. 4A, co-transfection of pDTD890-CAT with the I{kappa}BSR or dnNIK construct noticeably decreased the oltipraz-induced CAT activity although it was not statistically significant (p = 0.06). This result is consistent with our recent report suggesting that NF-{kappa}B alone accounts for only 20–30% of QR promoter activity in oltipraz-treated colon cancer cells, which was revealed by mutational analysis of the QR promoter region (17). We also determined the level of QR mRNA in the colon cancer cells after co-transfection of the inhibitory constructs, I{kappa}BSR and dnNIK. We found a dose-dependent decrease in mRNA levels by both dominant-negative mutants in oltipraz-treated HCT116 cells (Fig. 4B). The cells transfected with 3–9 µg of the constructs even showed a statistically significant decrease in QR mRNA expression compared with the cells transfected with empty expression vectors (Fig. 4C). This result indicates the importance of upstream signaling to NF-{kappa}B to determine QR expression after oltipraz treatment.



View larger version (31K):
[in this window]
[in a new window]
  		FIG. 4.
NF-{kappa}B is involved in QR gene regulation induced by oltipraz. A, inhibition of NF-{kappa}B signaling and QR promoter function. HCT116 cells (5 x 104) were co-transfected with 0.5 µg of pCMV-{beta}-gal vector and 1 µg of pDTD890-CAT or 1 µg of pCAT-basic control vector together with 1 µg of the I{kappa}BSR or dnNIK, or the empty expression vector, pcDNA3.1. After 24 h of transfection, the cells were treated with Me2SO (control) or 100 µM oltipraz for an additional 24 h. The cells were then analyzed using a CAT-ELISA kit as described under "Experimental Procedures." Normalized CAT activities were presented as fold induction relative to the activity obtained from the control group. The data shown are means ± S.D. of three independent experiments done in triplicate. B, effects of I{kappa}BSR and dnNIK on QR protein levels in HCT116 cells. The cells (5 x 105) were transfected with 3 µg of the empty expression vector, pcDNA3.1 or dominant negatives, I{kappa}BSR or dnNIK as indicated. After 24 h of transfection, the cells were treated with Me2SO (control) or 100 µM oltipraz for an additional 24 h, and were analyzed by Western blotting using anti-NQO1 antibody. The numbers below each band represent the mean fold induction of protein levels based on densitometric analysis from three independent experiments. The statistical significance of the difference between the empty vector-transfected group and dominant-negative-transfected groups were assessed by the two-sample Student's t test between two paired samples. One asterisk denotes the statistically significant difference with p values less than 0.05. C, effects of I{kappa}BSR and dnNIK on QR mRNA levels in HCT116 cells. The cells (5 x 105) were transfected with 3 µg of the empty expression vector, pcDNA3.1 or dominant negatives, I{kappa}BSR or dnNIK as indicated. After 24 h of transfection, the cells were treated with Me2SO (control) or 100 µM oltipraz for an additional 24 h. Total mRNA was then extracted and Northern blot analysis performed using a human QR cDNA probe to detect two QR mRNA transcripts (upper and lower bands). Equal loading of mRNA was monitored by hybridizing the same membrane with a glyceraldehyde-3-phosphate dehydrogenase (G3PDH) cDNA probe. Results from one of three independent experiments are shown. D, quantitation of QR mRNA levels. Bar graphs (means ± S.D.) represent quantitation of QR mRNA levels shown above. Densitometry readings of QR mRNA (lower transcript bands) were normalized to G3PDH levels and expressed as % control mRNA. The statistical significance of the difference between the empty vector-transfected group and dominant-negative-transfected groups were assessed by the two-sample Student's t test between two paired samples. One asterisk denotes the statistically significant difference with p values less than 0.05.

 
NIK and MEKK3 Are Both Involved in NF-{kappa}B Regulation by Oltipraz—Several MAP3K-related kinases including NIK and MEKK3 have been suggested to play a role in TNF-induced NF-{kappa}B regulation (30, 38). To examine whether any of these kinases are involved in NF-{kappa}B activation by oltipraz, we measured NIK and MEKK3 protein expression changes following oltipraz treatment in HCT116 cells. The expression of both NIK and MEKK3 was increased by oltipraz in a time-dependent manner (Fig. 5A). In order to confirm that both NIK and MEKK3 are essential for NF-{kappa}B activation, we transfected HCT116 cells with dnNIK or MEKK3-siRNA or its own expression vector, together with pNF-{kappa}B-Luc (Fig. 5B). MEKK3-siRNA was generated from a single nucleotide mismatch in a 19-nt sequence targeting MEKK3, and it suppressed MEKK3 expression compared with control transfected with the empty expression vector, pSilencer 1.0-U6 (Fig. 5B). Both of these inhibitory approaches caused a significant decrease in oltipraz-induced NF-{kappa}B transactivation (Fig. 5C). These results confirm that both NIK and MEKK3 are crucial signaling intermediates in oltipraz-induced NF-{kappa}B activation.



View larger version (28K):
[in this window]
[in a new window]
  		FIG. 5.
NIK and MEKK3 are involved in oltipraz-induced NF-{kappa}B signaling. A, time-dependent NIK and MEKK3 expression by oltipraz. Protein expression levels of NIK and MEKK3 were measured by Western blot analysis in HT29 and HCT116 cells. The cells (5 x 105) were treated with Me2SO (0 h control) or 100 µM oltipraz for the time periods indicated. Extracts (15 µg) from each cell line were applied to SDS-PAGE for Western blotting with anti-NIK and anti-MEKK3 antibodies. Quantitation of the Western blots was performed by densitometric scanning of the film using an image analysis system, ImageQuant 5.0 software. Densitometry readings of the bands were normalized to actin levels and expressed as fold induction relative to control (0 h). The numbers below each band represent the mean fold induction of protein levels based on densitometric analysis from three independent experiments. *, values differing statistically from control (p < 0.05; Student's t test). B, MEKK3 protein expression in MEKK3-siRNA transfected cells. 5–10 µg of MEKK3-siRNA or 5 µg of the empty expression vector, pSilencer 1.0-U6 were transfected into HCT116 cells (5 x 105) for 48 h and protein levels measured by Western blotting with anti-MEKK3 antibody. C, both NIK and MEKK3 are involved in oltipraz-induced activation of NF-{kappa}B. HCT116 cells (5 x 104) were co-transfected with 0.1 µg of pRL-CMV vector and 1 µg of pNF-{kappa}B-Luc or pTAL-Luc vector together with 1 µg of dnNIK or MEKK3-siRNA, or 1 µg of the empty expression vector, pcDNA3.1 or pSilencer 1.0-U6. After 24 h of transfection, the cells were treated with Me2SO (control) or 100 µM oltipraz for an additional 24 h. The cells were then analyzed using a Dual-Luciferase Reporter System as described under "Experimental Procedures." Normalized luciferase activities were presented as fold induction relative to the activity obtained from the control group. The data shown are means ± S.D. of three independent experiments done in triplicate. The statistical significance of the difference between the empty vector-transfected group and dominant-negative-transfected groups were assessed by the two-sample Student's t test between two paired samples. One asterisk denotes the statistically significant difference with p values less than 0.05.

 
Both IKK{alpha} and IKK{beta} Are Activated by MEKK3 and NIK— There is good evidence that MEKK3 and NIK can activate IKK{alpha} and IKK{beta} (26, 30), but the specific substrate specificity of each kinase is a matter of some controversy, and it is clear that the degree of activation of either IKK{alpha} or IKK{beta} may be dependent upon the nature of the external stimulus (39). To determine which IKK is affected by NIK and MEKK3 activation, we measured IKK{alpha} and IKK{beta} protein expression and kinase activity after transient transfection of dnNIK and MEKK3-siRNA in oltipraz-treated HCT116 cells. The cells were co-transfected with dnNIK or MEKK3-siRNA alone, or both. After 24 h, the cells were treated with 100 µM oltipraz for an additional 24 h and were analyzed by Western blotting (Fig. 6A). Both dnNIK and MEKK3-siRNA treatment decreased the content of both IKKs, and the effect was greatest when the inhibitors were used together. The cell extracts were also immunoprecipitated with anti-IKK{alpha} or anti-IKK{beta} antibodies for kinase assays (Fig. 6B). Both dnNIK and MEKK3-siRNA dramatically decreased both IKK{alpha} and IKK{beta} activity, the latter more potently than the former. When both forms of dominant negatives were added, the IKK{alpha} and IKK{beta} activities were further decreased. These data provide functional evidence that both MEKK3 and NIK are acting as upstream kinases for both IKK{alpha} and IKK{beta} in NF-{kappa}B regulation by oltipraz.



View larger version (15K):
[in this window]
[in a new window]
  		FIG. 6.
Oltipraz-induced IKK{alpha} and IKK{beta} activation is through NIK and MEKK3. HCT116 cells (5 x 105) were transiently transfected with 3 µg of dnNIK or 5 µg of MEKK3-siRNA alone, or both. After 24 h of transfection, the cells were treated with Me2SO (control) or 100 µM oltipraz for an additional 24 h and cell extracts resolved on SDS-PAGE for Western blotting (A) or immunoprecipitated with anti-IKK{alpha} or anti-IKK{beta} antibodies for kinase assay (B). Quantitation of the Western blots and kinase assay was performed by densitometric scanning of the film using an image analysis system, ImageQuant 5.0 software. Densitometry readings of the bands were normalized to actin levels and expressed as fold induction relative to control. IKK{alpha}/{beta} activity was normalized to IKK{alpha}/{beta} protein content in each kinase reaction and expressed as fold activation relative to the activity obtained in control. The numbers below each band represent the mean fold induction of protein levels or kinase activities based on densitometric analysis from three independent experiments. *, values differing statistically from the group treated with oltipraz alone (p < 0.05; Student's t test).

 
RIP Is Required for Oltipraz-induced NF-{kappa}B Signaling—RIP has been described to be a key effector for TNF-{alpha}-induced NF-{kappa}B activation (40). RIP is also known to be essential for the recruitment of IKK kinases in TNF-{alpha}-induced NF-{kappa}B signaling, although the kinase activity of RIP is not essential to this activation (41). Therefore, it is important to determine whether RIP is involved in the activation of NF-{kappa}B by oltipraz. We examined RIP expression by oltipraz and found a marked increase at 24 and 48 h post-treatment in HCT116 cells (Fig. 7A). We then tested whether RIP is required in oltipraz-induced NF-{kappa}B activation by using two different types of RIP deletion mutants: RIP-(1–300) and RIP-(569–671). The RIP protein contains three domains, including an N-terminal kinase domain, an intermediate domain and C-terminal death domain (42). RIP-(1–300) contains only the kinase domain and RIP-(569–671) contains only the death domain. After transfection, the cells were treated with 100 µM oltipraz for an additional 24 h and harvested for luciferase assay or Western blotting. The RIP deletion mutants significantly inhibited oltipraz-induced NF-{kappa}B transcriptional activation (Fig. 7B) as well as IKK{alpha}/{beta} expression through TNF receptor signaling (Fig. 7C). Depletion of TRADD, and lack of effect on TRAF2, imply a selective effect of oltipraz on intracellular components of TNF receptor signaling. These data suggest that RIP is an essential factor in oltipraz-induced NF-{kappa}B activation.



View larger version (30K):
[in this window]
[in a new window]
  		FIG. 7.
RIP is required for oltipraz-induced NF-{kappa}B signaling through RIP-MEKK3 interaction. A, expression of RIP in oltipraz-treated cells. HCT116 cells (5 x 105) were treated with Me2SO (control) or 100 µM oltipraz for 24 and 48 h and were then harvested for Western blotting analysis using an anti-RIP antibody. B, RIP deletion mutants inhibit oltipraz-induced NF-{kappa}B activation. The cells (5 x 104) were co-transfected with 0.1 µg of pRL-CMV vector and 1 µg of pNF-{kappa}B-Luc or pTAL-Luc vector together with 2 µg of each HA-tagged RIP deletion mutant; RIP-(1–300) or RIP-(569–671), or 2 µg of empty expression vector, pcDNA3-HA. After 24 h of transfection, the cells were treated with Me2SO (control) or 100 µM oltipraz for an additional 24 h. Normalized luciferase activities are presented as fold induction relative to the activity obtained from the control group. The data shown are means ± S.D. of three independent experiments done in triplicate. The statistical significance of the difference between the empty vector-transfected group and RIP deletion mutant-transfected groups were assessed by the two-sample Student's t test between two paired samples. One asterisk denotes the statistically significant difference with p values less than 0.05. C, RIP deletion mutants inhibit oltipraz-induced NF-{kappa}B signaling through the TNF-R1 pathway. HCT116 cells (5 x 105) were transfected with 5 µg of the empty expression vector, pcDNA3-HA, or HA-tagged RIP deletion mutants; RIP-(1–300) or RIP-(569–671). After 24 h of transfection, the cells were treated with Me2SO (control) or 100 µM oltipraz for an additional 24 h, and were analyzed by Western blotting using various antibodies. The numbers below each band represent the mean fold induction of protein levels based on densitometric analysis from three independent experiments. Statistical analysis was performed as mentioned as above. D, physical interaction between RIP and MEKK3. 500 µg of cell extracts were immunoprecipitated with 2 µg of anti-RIP antibody overnight, the immunoprecipitates resolved by SDS-PAGE, and Western blotting performed with anti-MEKK3 or anti-NIK. As a control for protein content, one percent of the cell extract from each sample was also loaded on the gel (1% input).

 
MEKK3 Interacts with RIP in Oltipraz-induced NF-{kappa}B Signaling—It has been reported that MEKK3 and NIK are critical protein kinases for the TNF-{alpha}-induced activation of NF-{kappa}B (30, 41, 43). In addition, interaction between MEKK3 and RIP is known to be an important feature of TNF-induced NF-{kappa}B activation (30). Since we found here that both MEKK3 and NIK play a role in oltipraz-induced NF-{kappa}B activation, we further examined whether MEKK3 or NIK interacts physically with RIP in oltipraz-induced NF-{kappa}B signaling by immunoprecipitation experiments. Total cell extracts were immunoprecipitated with anti-RIP antibody, and the immunoprecipitates were analyzed by Western blotting using anti-MEKK3 or anti-NIK antibodies. As shown in Fig. 7D, MEKK3 was clearly present in the immunoprecipitates from the oltipraz-treated cells, whereas we observed a very weak interaction with NIK. These data show that MEKK3, but not NIK, signaling is exerted through an interaction with RIP, implicating TNF receptor signaling in the oltipraz response.

Oltipraz Activates NF-{kappa}B through TNF-R1 Signaling—The proinflammatory cytokine TNF exerts its pleiotropic function by binding to one of two receptors, TNF-R1 and TNF-R2 (44). Ligand binding induces receptor trimerization and recruitment of several signaling proteins to the cytoplasmic domains of the receptors. In the case of TNF-R1, the first recruited protein is TRADD, binding of which recruits additional adaptor proteins, including RIP, TRAF2, and FAS-associated death domain (FADD). Since oltipraz treatment triggered formation of a RIP-MEKK3 complex as seen in TNF-induced NF-{kappa}B signaling (Fig. 7D), we examined the role of TNF-R1 in oltipraz-induced NF-{kappa}B signaling using a specific blocking antibody. HCT116 cells were preincubated with TNF-R1 blocking antibody (25 µg/ml) (or none) for 1 h and were treated with either TNF-{alpha} (100 ng/ml) for an additional 1 h, or oltipraz (100 µM) for 24 h. The cells were then analyzed by Western blotting using specific antibodies against TRADD, RIP, TRAF2, and IKK{beta} (Fig. 8). We found that TNF-{alpha} produced small increases in TRADD, RIP, TRAF-2, and IKK{beta} that were abrogated by preincubation with TNF-R1 blocking antibody. Oltipraz treatment resulted in greater expression of all of these proteins, and the increases were attenuated but not completely abrogated by preincubation with the TNF-R1 antibody. Consistent with the data in Fig. 7, the major effects are on RIP and IKK{beta}, both of which increase with oltipraz treatment, an effect largely abrogated by receptor blockade. These data suggest that oltipraz-induced NF-{kappa}B signaling is exerted through activation of the TNF-R1 complex.



View larger version (19K):
[in this window]
[in a new window]
  		FIG. 8.
Oltipraz activates NF-{kappa}B through TNF-R1 signaling. A, effects of blocking TNF-R1 on oltipraz-induced NF-{kappa}B signaling. HCT116 cells (5 x 105) were preincubated with a blocking antibody against TNF-R1 (25 µg/ml) (or none) for 1 h, and the cells were then treated with TNF-{alpha} (100 ng/ml) for 1 h or oltipraz (100 µM) for 24 h for the co-treatments. After the treatments, the cells were harvested and analyzed by Western blotting using specific antibodies against TRADD, RIP, TRAF2, and IKK{beta}. The numbers below each band represent the mean fold induction of protein levels based on densitometric analysis from three independent experiments. B, quantitation of the Western blots in A, above. Quantitation of the Western blots was performed by densitometric scanning of the film using an image analysis system, ImageQuant 5.0 software. Densitometry readings of the Western blots were normalized to actin levels and expressed as fold induction relative to the expression obtained in control. Bar graphs (means ± S.D.) represent quantitation of protein levels from three independent experiments shown in A. Values bearing different superscripts differ significantly (p < 0.05). Statistical analysis was performed using one-way analysis of variance. Where a significant effect was found, Fisher's least significant difference test for multiple comparisons was used to identify differences between groups.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
Oltipraz is a candidate chemoprevention agent that was developed based upon its ability to upregulate detoxication genes and so to protect normal cells from mutagenic insults (14). It was demonstrated early that the effect on detoxication genes is exerted through transcriptional induction, and various promoter elements have been shown to be important in this action (9, 31). Though oltipraz has a number of side effects that may impinge upon its value as a chemopreventive agent for broad use in the population, the importance of its mechanism of induction of detoxication genes as a means of protecting tissues is not in question. It is therefore critical to understand the biological pathways by which oltipraz exerts these effects. Our previous studies showed that two cis-acting elements, AP-1 and NF-{kappa}B, are involved in human QR gene regulation (16, 31). In this report, we have focused on NF-{kappa}B regulation by oltipraz. NF-{kappa}B has been shown to play an important role in regulating anti-apoptotic and pro-apoptotic events, depending on the physiological circumstances (45). We show here that the NF-{kappa}B dominant-negative mutants clearly inhibited QR promoter activity and mRNA expression confirming that NF-{kappa}B is one of the essential factors accounting for QR gene regulation in oltipraz-treated colon cancer cells.

To establish the upstream signaling mechanisms of NF-{kappa}B activation by oltipraz, we have examined the sequence of events that lead to QR expression in the colon cell model. We found that MEKK3 and RIP both play an essential role in oltipraz-induced NF-{kappa}B signaling. Our data suggest that MEKK3 was required for IKK{alpha} and IKK{beta} activation and that it interacted physically with RIP in mediating the activation. Several members of the mitogen-activated protein kinase kinase kinase (MAP3K) family including MEKK1 (25), MEKK2 (26), MEKK3 (26), NIK (27), TBK1 (28) and TAK1 (29) have been suggested to activate IKK when overexpressed. However, some of these do not appear to be physiologically relevant, since genetic studies reveal that absence of MEKK1 (46), and NIK (47) do not affect IKK activation in vivo. A recent study has reported that MEKK3 has a critical role for activation of TNF-induced NF-{kappa}B signaling (30). While NIK had been eliminated as a candidate IKK kinase in cellular models (40), we included NIK in our study to test IKK activation because the dominant negative of NIK had decreased QR mRNA levels (Fig. 4, B and C). Both MEKK3 and NIK showed similar potency to activate oltipraz-induced NF-{kappa}B transactivation, and while MEKK3 showed a somewhat greater ability to activate both IKK{alpha} and IKK{beta} than did NIK, both were active in this regard too (Fig. 6). Therefore, we believe that MEKK3 and NIK are essential kinases for IKK activation in oltipraz-induced NF-{kappa}B signaling.

Because RIP is known to be one of essential effectors in TNF-{alpha}-mediated IKK activation (41), we examined whether RIP is involved in oltipraz-induced NF-{kappa}B signaling by interacting with MEKK3 or NIK. Not only did we observe an essential role of RIP in oltipraz-induced NF-{kappa}B signaling confirmed by transfection experiments using RIP deletion mutants (Fig. 7, B and C), we also found a physical interaction with MEKK3 as measured by coimmunoprecipitation experiments with RIP (Fig. 7D). However, when we examined the physical interaction between RIP and NIK after oltipraz treatment, it was unchanged compared with the basal level (Fig. 7D). Although NIK has no significant interaction with RIP, it did show some effects on NF-{kappa}B and IKK activation in oltipraz-treated cells (Figs. 5C and 6, respectively). This result suggests that NIK may activate the IKK {alpha}/{beta} complex independently of RIP, since NIK is known to interact with the IKK {alpha}/{beta} heterocomplex form (27), and to activate IKK {alpha}/{beta} as shown by NF-{kappa}B activation following overexpression of NIK (26, 48). Therefore in oltipraz signaling, two pathways to IKK activation are induced, one through the RIP-MEKK3 complex and the other through NIK by as yet undetermined signals.

We hypothesize based on these data that oltipraz-induced NF-{kappa}B signaling occurs through the TNF-{alpha} receptor 1 (TNF-R1) complex. This possibility is supported by the fact that the presence of the RIP-MEKK3 complex is required in the TNF-R1 complex for the activation of IKK in TNF-{alpha}-mediated NF-{kappa}B signaling (30). Although we observed a requirement for RIP and the presence of RIP-MEKK3 complexes in oltipraz-induced NF-{kappa}B signaling, further clarification of TNF-R1-dependent signaling by oltipraz was required. Thus, we investigated whether the TRADD and TRAF2 in addition to RIP are also involved in this pathway since both molecules are essential for TNF-R1-dependent NF-{kappa}B activation. We found that IKK{beta} and RIP levels were decreased after blocking TNF-R1 (Fig. 8). We also examined if oltipraz caused the cells to produce TNF-{alpha} for triggering TNF-R signaling. We found that there is no significant increase in TNF-{alpha} production by 100 µM oltipraz at any of time points tested (data not shown). This implies that oltipraz-induced TNF-R signaling is not a consequence of the autocrine action of TNF-{alpha}, but could depend on intracellular regulation of TNF-R signaling. Taken together, these data suggest that oltipraz triggers NF-{kappa}B signaling through intracellular TNF-R1 activation, the mechanism of which is currently under investigation. Since RIP and TRAF2 either directly or indirectly interact with both TNF-R1 and TNF-R2 for NF-{kappa}B transcriptional activation (40), TNF-R2 signaling is another plausible target for future investigation.

The activation of IKK{alpha} by NIK stimulated us to investigate the alternative pathway of NF-{kappa}B signaling via RelB/p100 processing described previously (49). In this non-classical pathway, the p100 precursor is bound by RelB in the cytoplasm and upon proteasomal processing (stimulated by IKK{alpha}), releases p52 in a RelB heterodimer that undergoes nuclear translocation and interaction with NF-{kappa}B-responsive genes. We found that there was no increase of RelB and p52 in nuclear extracts after oltipraz stimulation (data not shown), and so ruled out this pathway as an important component of the action of oltipraz in colon cells.

We also noted some differences among the two cell lines used as models in these experiments. NF-{kappa}B signaling involves various intermediate proteins and is a multistep process. We investigated expression of several of these proteins and found a significant increase in their levels by 100 µM oltipraz treatment in both HT29 and HCT116 cells (Fig. 1). It is interesting to note that all of the proteins examined showed higher expression in HCT116 cells compared with HT29 cells. We speculate that this is may be due to the different p53 status between two cell lines: HT29 cells contain p53+/– but no functional activity, and HCT116 cells are p53+/+. A recent study has reported that p53 can enhance NF-{kappa}B DNA binding activity (50). A clear elevation of NF-{kappa}B DNA binding activity was observed after introduction of p53 in cells that do not express endogenous p53 (50). Here we found that oltipraz caused greater activation of NF-{kappa}B in HCT116 compared with HT29 cells (Fig. 2), suggesting that NF-{kappa}B activation might depend on p53 status. This finding would be expected to be an advantage for the use of oltipraz as a chemoprevention agent, since the target tissue should have normal p53 function.


   FOOTNOTES
 
* This work was supported by Grant CA-78272 from the NCI, National Institutes of Health. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

{ddagger} To whom correspondence should be addressed: School of Medicine, 51 N. 39th St., MAB-103, Philadelphia, PA 19104. Tel.: 215-662-8636; Fax: 215-243-3269; E-mail: peter.odwyer{at}uphs.upenn.edu.

1 C. W. Nho, manuscript in preparation. Back

2 The abbreviations used are: QR, quinone reductase; NF-{kappa}B, nuclear factor-{kappa}B; IKK{alpha}, I{kappa}B kinase {alpha}; IKK{beta}, I{kappa}B kinase {beta}; NIK, NF-{kappa}B inducing kinase; MEKK3, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 3; RIP, receptor-interacting protein; TNF, tumor necrosis factor; TNF-R1, TNF receptor 1; I{kappa}BSR, I{kappa}B superrepressor; dnNIK, dominant-negative NIK; CAT, chloramphenicolacetyltransferase; TRAF, TNF receptor-associated factor; nt, nucleotide; ELISA, enzyme-linked immunosorbent assay; TRADD, TNF receptor-associated death domain; EMSA, electrophoretic mobility shift assay; HA, hemagglutinin. Back


   ACKNOWLEDGMENTS
 
We thank Karen Vousden (NCI, National Institutes of Health) for kindly providing dominant-negative mutants, I{kappa}BSR and dnNIK. We also thank Toshiyuki Miyashita (National Research Institute) for providing RIP deletion mutants, RIP-(1–300) and RIP-(569–671).



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Sporn, M. B., and Suh, N. (2002) Nat. Rev. Cancer 2, 537–543[CrossRef][Medline] [Order article via Infotrieve]
  2. Hong, W. K., and Sporn, M. B. (1997) Science 278, 1073–1077[Abstract/Free Full Text]
  3. Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L., and Wolmark, N. (1998) J. Natl. Cancer Inst. 90, 1371–1388[Abstract/Free Full Text]
  4. Sharma, R. A., Manson, M. M., Gescher, A., and Steward, W. P. (2001) Eur. J. Cancer 37, 12–22[Medline] [Order article via Infotrieve]
  5. Steinmetz, K. A., and Potter, J. D. (1991) Cancer Causes Control 2, 325–357[CrossRef][Medline] [Order article via Infotrieve]
  6. Steinmetz, K. A., and Potter, J. D. (1996) J. Am. Diet. Assoc. 96, 1027–1039[CrossRef][Medline] [Order article via Infotrieve]
  7. Verhoeven, D. T., Goldbohm, R. A., van Poppel, G., Verhagen, H., and van den Brandt, P. A. (1996) Cancer Epidemiol. Biomarkers Prev. 5, 733–748[Abstract]
  8. van Poppel, G., Verhoeven, D. T., Verhagen, H., and Goldbohm, R. A. (1999) Adv. Exp. Med. Biol. 472, 159–168[Medline] [Order article via Infotrieve]
  9. Kwak, M. K., Egner, P. A., Dolan, P. M., Ramos-Gomez, M., Groopman, J. D., Itoh, K., Yamamoto, M., and Kensler, T. W. (2001) Mutat. Res. 480–481, 305–315
  10. O'Dwyer, P. J., Johnson, S. W., Khater, C., Krueger, A., Matsumoto, Y., Hamilton, T. C., and Yao, K. S. (1997) Cancer Res. 57, 1050–1053[Abstract/Free Full Text]
  11. Clapper, M. L. (1998) Pharmacol. Ther. 78, 17–27[CrossRef][Medline] [Order article via Infotrieve]
  12. Szarka, C. E., Yao, K. S., Pfeiffer, G. R., Balshem, A. M., Litwin, S., Frucht, H., Goosenberg, E. B., Engstrom, P. F., Clapper, M. L., and O'Dwyer, P. J. (2001) Cancer Detect. Prev. 25, 352–361[Medline] [Order article via Infotrieve]
  13. Kensler, T. W., He, X., Otieno, M., Egner, P. A., Jacobson, L. P., Chen, B., Wang, J. S., Zhu, Y. R., Zhang, B. C., Wang, J. B., Wu, Y., Zhang, Q. N., Qian, G. S., Kuang, S. Y., Fang, X., Li, Y. F., Yu, L. Y., Prochaska, H. J., Davidson, N. E., Gordon, G. B., Gorman, M. B., Zarba, A., Enger, C., Munoz, A., Helzlsouer, K. J., et al. (1998) Cancer Epidemiol. Biomarkers Prev. 7, 127–134[Abstract]
  14. Benson, A. B., 3rd. (1993) J. Cell. Biochem. 17F, (suppl.) 278–291[CrossRef]
  15. O'Dwyer, P. J., Clayton, M., Halbherr, T., Myers, C. B., and Yao, K. (1997) Clin. Cancer Res. 3, 783–791[Abstract]
  16. Yao, K. S., and O'Dwyer, P. J. (1995) Biochem. Pharmacol. 49, 275–282[CrossRef][Medline] [Order article via Infotrieve]
  17. Yao, K. S., and O'Dwyer, P. J. (2003) Biochem. Pharmacol. 66, 15–23[CrossRef][Medline] [Order article via Infotrieve]
  18. Siebenlist, U., Franzoso, G., and Brown, K. (1994) Annu. Rev. Cell Biol. 10, 405–455[CrossRef][Medline] [Order article via&